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Pflanzliches Trio in der Behandlung nervöser 
Unruhe bei Kindern 
Zusammenfassung Emotionale Probleme und Verhal-
tensauffälligkeiten bei Kindern und Jugendlichen sind 
keine Ausnahme. Inwieweit Kindern, die seit etwa 2 
Jahren unter nervöser Unruhe (unter anderem aufgrund 
agitierter Depression) litten, durch eine Behandlung 
mit einem pflanzlichen Kombinationspräparat geholfen 
werden kann, zeigt eine multizentrische, prospektive 
Beobachtungsstudie (2008) mit 115 Kindern im Alter 
von 6 bis 12 Jahren. Nach Einschätzung der Eltern zeig-
te sich eine klare Besserung insbesondere bei Konzen-
trationsstörungen, sozialem Rückzug, bei Kindern, die 
unter Ängsten und/oder Depressionen litten. Basierend 
auf der Beurteilung der Ärzte waren 81,6–93,9  % der 
Kinder am Ende der Beobachtungszeit beschwerdefrei 
oder hatten nur noch leichte Beschwerden in Bezug 
auf neun der dreizehn untersuchten Symptome, wie 
Depressionen, Schul-/Prüfungsangst, sonstige Ängste, 
Schlafstörungen und verschiedene physische Probleme. 
Der therapeutische Erfolg war unabhängig von weite-
ren Therapien oder Begleitmedikation aufgrund der 
Einschlussdiagnose. Die Behandlung wurde gut vertra-
gen. Die verwendeten Pflanzenextrakte wurden aus Jo-
hanniskraut, Baldrianwurzel und Passionsblumenkraut 
gewonnen.
Schlüsselwörter: Nervöse Unruhe, Angst, Depression, 
Pflanzenextrakte, Kinder
Summary Emotional and behavioral problems in chil-
dren and adolescents are no exception. To what extent a 
fixed plant extract combination is able to support chil-
dren suffering from nervous agitation due to agitated 
depression among others for approximately 2 years has 
been investigated in a multicenter, prospective obser-
vational study (2008) with 115 children between 6 and 
12 years. Assessments of the parents showed a distinct 
improvement in children who had attention problems, 
showed social withdrawal, and/or were anxious/depres-
sive. Based on the physicians’ assessment, 81.6–93.9  % 
of the affected children had no or just mild symptoms 
at the end of observation concerning nine of thirteen 
evaluated symptoms such as depression, school/exami-
nation anxieties, further anxieties, sleeping problems, 
and different physical problems. Therapeutic success 
was not influenced by additional medication or thera-
pies. The treatment was well tolerated. The used plant 
extracts have been gained from St. John’s Wort herb, va-
lerian root, and passionflower herb.
Keywords: Nervous agitation, Anxiety, Depression, 
Plant extracts, Children
 Introduction
Especially, young people need a strong mental well-being 
to cope with all the intricacies of life. However, during 
the last 16 years, the number of children and adoles-
cents showing psychosomatic symptoms is consistently 
high. There might be no epidemic [1], but the following 
numbers are alarming anyway. In any given year, world-
wide 20  % of young people experience a mental health 
problem, most commonly depression or anxiety [2]. In 
Austria, pupils every day or at least several times a week 
suffer from sleep disorders (17.2 %), headache (14.4 %), 
petulance (14.2 %), nervousness (11.7 %), and/or back-
ache (11.7 %) [3]. Similar numbers have been measured 
in other countries, e.g., in Canada, 21–27  % of grade 6 
adolescents feel depressed at least once a week, 21  % 
of children at 2–5 years of age suffer from high levels of 
emotional problems, anxiety problems, lack of concen-
tration, and/or hyperactivity [4, 5].These numbers are 
similar in other countries. In Germany, every sixth child 
or adolescent shows psychiatric disorders [6, 7].
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There is a scientific consensus that these children (and 
their families) have to be supported and treated with 
adequate therapies [7–9], at least because children with 
anxieties and depressive episodes are at increased risk 
for severe emotional problems in adolescence and adult-
hood [10]. The broad range of interventions for anxieties, 
nervousness, and depression involve cognitive behav-
ioral therapy as well as mostly chemical antidepressants, 
anxiolytics, and hypnotics [11–13]. Especially, treatment 
with traditional allopathic medication is controversially 
discussed addressing efficacy and safety of psychotropic 
agents in pediatrics. Due to the potential for side effects 
and addiction, prolonged treatment with chemical drugs 
as it is recommended by the WHO is often accompanied 
by simultaneous impairment of quality of life [7, 9, 12, 
14, 15]. As a result, there is a clear increasing demand 
for complementary and alternative medicine [16] such 
as a unique combination of extracts from Hypericum 
perforatum (St. John’s Wort), Passiflora incarnata (Pas-
sionflower), and Valeriana officinalis (Valerian). Beyond 
traditional knowledge about the usage of Hypericum in 
treatment of mood and sleep disorders, recent studies 
have shown various effects on central neurotransmitter 
systems [17, 18] and the ability to act similar to conven-
tional antidepressive drugs [18–20]. The experimentally 
verified synergistic effect of Passiflora on Hypericum 
enables application of a small amount of Hypericum with 
a simultaneous high efficacy. This reduces the probabil-
ity of side effects [21] and leads to effects more compa-
rable to the impact of Fluoxetine than to the impact of St. 
John’s Wort extract alone [22]. Passiflora is traditionally 
used in combination with other herbs as a mild sedative 
[23, 24]. The third plant, Valerian, is traditionally used in 
medical conditions of sleep disorders and nervous agita-
tion [25]. The combination of all the three medical plants 
act on gamma-amino butyric acid (GABA) and serotonin 
(5-HT) receptors, which are recognized targets of phar-
macological antidepressant treatment [26].
The aim of this observational study was the evaluation 
of safety and effectiveness of the treatment of nervous 
agitation due to affective disorders in children between 6 
and 12 years of age with a fixed herbal combination con-
taining St. John’s Wort, Valerian, and Passionflower.
 Material and methods
 Study objectives
After more than 40 years of experience with these plant 
extracts, we hypothesized that a combination of St. John’s 
Wort, Valerian, and Passionflower has positive impact on 
children with nervous agitation due to affective disorders.
 Study duration
The duration of the study was from March 2008 to Novem-
ber 2009.
 Study design
This multicenter, prospective observational study was 
conducted by 17 physicians (15 pediatricians, 1 neurolo-
gist, and 1 general practitioner) in Germany.
Concept and design of the study as well as its ethical 
validity and performance are based on the actual rec-
ommendations of the Bundesinstitut für Arzneimittel 
und Medizinprodukte (BfArM, German Federal Insti-
tute for Drugs and Medical Devices) and referred to the 
Declaration of Helsinki and Good Clinical Practice. The 
study was registered on Clinical Trials under the trial 
registration number NCT 01125579. Furthermore, this 
study followed the actual strengthening the reporting of 
observational studies in epidemiology (STROBE) guide-
lines for items to be included in reports on observational 
studies [27].
 Study setting
Before the start of this study, the physicians got a brief-
ing on the observational plan, the ethical and scientific 
basis of this multicenter, prospective observational study 
with observational character, the allocation procedure, 
and the therapy schedule in accordance with the study 
protocol. Data assessment included a physician-com-
pleted questionnaire and a standardized parent-report 
questionnaire (Child Behavior Checklist (CBCL/4-18)) 
on three occasions: before the treatment (visit 1, base-
line), after approximately 2 weeks of the treatment (visit 
2), and after approximately 4 weeks of the treatment (visit 
3). The time point of final documentation was set at the 
physicians’ own discretion. The concomitant diseases 
were grouped according to the ICD-10 classification. All 
medications apart from the study medication were clas-
sified according to the—to that time current—“Rote Liste 
2008”.
 Study participants
The children were chosen by the responsible physician 
and enrolled after the informed written consent, and a 
data privacy policy statement had been obtained from 
their legal guardian. Information of possible unwanted 
side effects and the possibility to cancel the participation 
at any time without any negative impact on the treatment 
of the child were given to the legal guardian.
Inclusion criteria were defined as follows: 6–12 years 
of age, history of nervousness and agitation (including 
agitated depression) due to affective disorders, informed 
consent to participate in the prospective cohort study 
obtained from the legal guardian. Exclusion criteria con-
tained children younger than 6 years or older than 12 
years of age, hypersensitivity to any of the ingredients, 
history of skin hypersensitivity to light, receiving photo-
therapy, or any photodiagnostic procedures.
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 Variables studied
Target parameters for effectiveness were the influence of 
child’s disease on everyday life of the family, the course 
of common symptoms, and the change in the parent’s 
questionnaire CBCL (Table 1).
 Interventions
Doses and duration of the treatment with herbal medi-
cine were at the respective physician’s discretion. The 
combination of three special dry extracts from Hypericum 
perforatum (St. John’s Wort herb), Valeriana officinalis 
(Valerian root), and Passiflora incarnata (Passionflower 
herb; Table 2) has been administrated as tablet via oral 
route. Study medication was prescribed by a physician 
and bought by the patient’s legal guardian.
 Results
 Participants
Altogether 31 physicians were invited to collect data and 
17 physicians agreed to participate in the study. They gath-
ered correctly and completely filled-out case report forms 
of 115 children. Therefore, the participant rate was 54.8 %.
 Descriptive data
The patient group involved in this study consisted of 69 
boys (60 %) and 45 girls (39.1 %). No statement of sex was 
made for one child, which explains the missing 0.9 %. In 
average, the children were 9.4 years old (± 1.6) with an 
average weight about 35.4 kg (± 9.6). The inclusion diag-
nosis “nervous agitation” was made on average about 2.3 
years ago. So, in the huge majority of the treated children 
(92.6  %), a subchronic or chronic pattern of symptoms 
was already present.
Period of the treatment enfolded 2 weeks (n = 14), 
including visit 1 and visit 2 or about 4 weeks (n = 101) 
including all the three visits (Table 1). The average daily 
dose was 2–3 tablets in accordance with the recommend 
dose of 1–3 tablets per day.
During the observation period, 16 children (13.9  %) 
received additional medications related to the inclusion 
diagnosis, mainly hypnotics/sedatives (64  %) and psy-
chopharmaceuticals/psychoanaleptics (12  %). Eighty-
four percentages of the respective drugs were used as 
long-term medication. Up to three nonmedical therapies 
were reported for 61 children (53  %) such as psycho-
logical/psychotherapeutic care (46.6 %) and progressive 
relaxation (19.2 %).
Concomitant diseases were mentioned for 21 children 
(18.3  %), mainly emotional and behavioral disorders 
(40.7 %) and diseases of the respiratory system (18.5 %). 
For 14 children (12.2  %) concomitant medication was 
reported, mainly broncholytics/antiasthmatics, antial-
lergics, and dermatologics.
 Impairment of ordinary family life
Behavioral disorders of children and their therapies 
always affect the everyday family life. At the first visit, 
parents estimated the impact via a visual analogue scale 
with 5.95 in the mean. After the treatment, this average 
value improved to 3.86. Altogether, a clearly positive 
development was achieved in 86.7 % of children.
 Child behavior questionnaire
Evaluation of the CBCL displays a detailed picture of the 
parents’ assessment from the beginning until the end 
of the observation time. In comparison to children of 
Table 1. Study course
Assessment criteria Visit 1 Visit 2 Visit 3
Demographic data (sex, age, body height, and 
body weight)
X – –
Concomitant therapy due to inclusion diagnosis X – –
Concomitant medication in general and due to 
inclusion diagnosis
X – –
Efficacy and tolerability of previous therapy due 
to inclusion diagnosis
X – –
Impairment to everyday life of the family by 
child’s complaints (filled in by legal guard-
ian; visual analogue scale; 0 = no limitation; 
10 = extreme limitation)
X X X
CBCL/4-18 (filled in by legal guardian) X X X
Common symptoms such as learning disorders, 
speech disorders, lack of concentration, school/
examination anxieties, other anxiety disorders, 
aggressiveness/irritability, depression, uncoordi-
nated hyperkinesia, tiredness/fatigue, problems 
falling asleep, problems staying asleep, head-
ache, and abdominal/stomach pain (filled in by 
physician; 0 = nothing; 3 = strong)
X X X
Drug changes (newly prescribed, withdrawn, 
dosage decreased, and dosage increased)
X X
Tolerability – X X
Adverse drug reactions – X X
CBCL child behavior checklist
Table 2. Composition of one tablet of study medication






Dried extract of St. John’s 
Wort herb (Hypericum perfo-
ratum L.)
Ethanol 38 % 4.6–6.5:1 60
Dried extract of Valerian root 
(Valeriana officinalis L.)
Ethanol 40 % 3.8–5.6:1 28
Dried extract of Passionflower 
herb (Passiflora incarnata L.)
Ethanol 60 % 6.25–7.1:1 32
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the same age, most of the children (up to 87.0  %) were 
assessed as “normal” concerning items of the compe-
tency scales at all visits. Some children showed aspects of 
“borderline abnormal” (up to 11.3 %) or “abnormal” (up 
to 13.0 %) behavior.
Until the end of the observation most children kept 
their level. According to which the competency scale 
is viewed two to five children aggravated in their prob-
lems, while an improvement was achieved for nine to ten 
children.
Analysis of syndrome scale items also showed that 
most children behaved “normal” (85.2–64.3 %, depend-
ing on the scale). The majority of children were stabi-
lized in a normal behavior under the treatment. Slight 
aggravation of single participants was detectable in 
items of a schizoid/compulsive (four children) or disso-
cial behavior (three children). The highest proportion of 
“borderline normal” or “abnormal”-behaving children 
were detectable in the two scales “attention problems” 
(35.7 %) and “anxiety/depression” (29.6 %) (Fig. 1).
Figure 1 gives an overview of the number of affected 
children, and the development they underwent dur-
ing the therapy. A clear improvement was reported by 
legal guardians, whose children had attention problems, 
showed social withdrawal, and/or were anxious/depres-
sive. Between 61.0 and 87.0  % of the affected children 
developed positively. In the same range was the progress 
of children with physical and/or social problems. Even 
children with a schizoid/compulsive behavior improved 
in their development. A little lower was the percentage 
of children with a clear progress when the participants 
showed dissocial (47.1  %) and/or aggressive behavior 
(50 %) at the beginning of the observation.
Altogether, up to 69.6 % of children who were assessed 
as “borderline abnormal” or “abnormal” reached a “nor-
mal” assessment at the end of the observation period. 
The therapeutic success was not influenced by concomi-
tant medication or therapies due to inclusion diagnosis.
 Assessment of common symptoms by the 
physician
The statements about the problems of children with 
nervous agitation given by the CBCL were confirmed by 
physicians in aspects such as the high number of chil-
dren affected by attention problems, anxiety/depression, 
aggressiveness, and/or physical problems. In addition to 
this, the results of the symptom query presented more 
details in some aspects. The scale “anxiety/depression” 
is divided into three symptoms, which showed that the 
amount of children suffering from examination anxiet-
ies (59.1 %) or other anxiety disorders (42.6 %) was much 
higher than the number of depressive children (29.6 %) 
in this study. Physical problems are also mentioned 
for lots of children such as tiredness/fatigue (54.8  %), 
abdominal/stomach pain (39.1  %), and/or headache 
(42.6 %). Problems to fall or stay asleep were mentioned 
in 53.9 and 33.9 % of the children, respectively. After the 
treatment, 81.6–93.9 % of the affected children had no or 
just mild symptoms concerning nine of thirteen evalu-
ated symptoms such as depression, school/examination 
anxieties, further anxieties, sleeping problems, and dif-
ferent physical problems (Fig. 2). The percentage of chil-
dren suffering from symptoms such as uncoordinated 
hyperkinesia, aggressiveness/irritability, lack of concen-
tration, and learning disorders was clearly reduced in the 
end, too. Between 50.8 and 73.0 % of children with these 
problems had no or just mild symptoms in the end.
In general, concomitant therapies or medication due 
to inclusion diagnosis did not affect the efficacy. At the 
end of the observation period, the number of children 
with just slight or no problems tended to be higher in 
cases without concomitant medication in learning prob-
lems/partial performance problems and problems in 
falling asleep. A tendency for a better result with con-
comitant medication was reported for compulsive unco-
ordinated movements.
 Tolerability
A good tolerability was reported for 97.4  % of the chil-
dren. In seven cases, the tolerability was described as 
moderate or poor, because of paradox reactions (restless-
ness, weepiness, increased irritability, or aggressiveness) 
Fig. 1 Change in syndrome scales until the end of the obser-
vation period. Depiction of the number of affected children, 
whose problems improved, remained unchanged, or dete-
riorated during the treatment. The classification in syndrome 
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or other adverse events such as redness in cheekbone 
region (one case) or stomach pain (one case). All events 
were considered to have a possible relation to the study 
treatment.
In 53 children (46.1  %), the therapy was continued 
after the end of the prospective cohort study.
 Discussion
Contrary to various other diseases, nervous agitation 
due to depressive episodes is not measurable by definite 
laboratory findings. Each child shows an individual set 
of few to various symptoms with further variations in 
intensity. This is also reflected by the assessments of par-
ents, other legal guardians, and physicians taking part in 
the presented study. Typical symptoms of the examined 
children were attention problems, anxieties, depres-
sion, and psychosomatic problems. However, approxi-
mately 40–50  % of children with these disorders do not 
have a response to medication or behavioral therapy 
alone [28, 29], and a combination of both is more effec-
tive [30]. On the other hand, psychotropic medications 
are used too early [7] and about 25 % of depressive ado-
lescents develop substance abuse [31]. So, parents pre-
fer nonmedical therapies as initial treatment because of 
the higher risk of side effects in therapies with chemical 
medication [30]. For these families, the tested herbal 
combination of St. John’s Wort, Valerian, and Passion-
flower offers a good alternative and fulfills the requested 
aspects. A good tolerability is represented by just a few 
mild and transient side-effects. The assessments of par-
ents and physicians displayed a good efficacy on a broad 
spectrum of symptoms linked to inclusion diagnosis. 
Moreover, it is possible to adjust the treatment individu-
ally because the good efficacy was independent from 
concomitant nonmedical and medical therapies—with 
three exceptions. In situations of learning problems and 
problems falling asleep, the treatment without concomi-
tant drug therapy due to inclusion diagnosis tended to 
be more successful. In comparison to that treatment of 
uncoordinated hyperkinesia seemed to be more effective 
with concomitant medication.
Another advantage for use of the study medication in 
initial therapies is the fast onset: 3 h after first intake [22]. 
The experiences collected by long marketing history and 
supported by the recent results of the presented study 
showed that the study medication is useful in situations 
of psychological mood disorders and sleep disorders due 
to nervousness also in children between 6 and 12 years 
of age.
 Limitations
Due to the officially required design of a multicenter, pro-
spective observational study some limitations are given. 
Therefore, it is unavoidable that safety and effectiveness 
are observed without a placebo group and randomiza-
tion. Lack of blinding, the subjectivity of assessments, 
and the potential impact of the relationship between 
child, parents, and physician on the child’s development 
may also be limitations. On the other hand, this type of 
study offered the possibility to prove the medication’s 
Fig. 2 Affected children with 
just mild or without symptoms 
at the end of the observa-
tion period. Classification 
of children based on the 
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tolerability and effectiveness in everyday life beyond a 
strictly controlled environment of a clinical study.
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